MTEM - Molecular Templates Inc Stock Price, Fair Value and News

1.45USD-0.05 (-3.33%)Market Closed

Market Summary

USD1.45-0.05

Market Closed

-3.33%

MTEM Stock Price

View Fullscreen

MTEM RSI Chart

MTEM Valuation

Market Cap

9.5M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

0.3

EV/EBITDA

-922.54

Price/Free Cashflow

-0.34

MTEM Price/Sales (Trailing)

MTEM Profitability

EBT Margin

-25.61%

Return on Equity

-313.41%

Return on Assets

-67.84%

Free Cashflow Yield

-292.28%

MTEM Fundamentals

MTEM Revenue

Revenue (TTM)

31.8M

Rev. Growth (Yr)

-69.73%

Rev. Growth (Qtr)

58.01%

MTEM Earnings

Earnings (TTM)

-18.4M

Earnings Growth (Yr)

-94.73%

Earnings Growth (Qtr)

114.49%

Breaking Down MTEM Revenue

Last 7 days

-2.0%

Last 30 days

-8.2%

Last 90 days

-61.2%

Trailing 12 Months

224.4%

How does MTEM drawdown profile look like?

MTEM Financial Health

Current Ratio

1.25

Debt/Equity

6.2

Debt/Cashflow

-0.76

MTEM Investor Care

Shares Dilution (1Y)

75.25%

Diluted EPS (TTM)

-1.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	31.8M	0	0	0
2023	47.9M	50.3M	52.9M	57.3M
2022	44.0M	33.2M	35.1M	19.8M
2021	17.9M	26.1M	24.2M	38.7M
2020	19.4M	20.9M	21.5M	18.8M
2019	19.8M	23.9M	20.8M	22.3M
2018	2.0M	3.3M	9.4M	13.3M
2017	2.3M	2.6M	3.0M	3.4M
2016	0	0	39.4M	1.9M
2015	14.7M	14.7M	14.7M	76.9M
2014	13.3M	13.8M	14.3M	14.7M
2013	8.5M	9.9M	11.3M	12.5M
2012	1.3M	2.6M	3.9M	5.9M
2011	0	0	0	62.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Molecular Templates Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	biotech target n v	bought	587,500	2.35	250,000	-
Apr 02, 2024	lalande kevin m.	acquired	411,250	2.35	175,000	-
Jul 17, 2023	biotech target n v	bought	2,000,000	0.47	4,255,320	-
Jul 07, 2022	kim jason s.	acquired	8,583	0.71	12,089	see remarks
Jun 16, 2022	mclennan sean	bought	24,477	0.8159	30,000	see remarks
Jun 15, 2022	shv management services, llc	bought	55,180	0.89	62,000	-
Jun 15, 2022	lalande kevin m.	bought	55,180	0.89	62,000	-
Jun 14, 2022	lalande kevin m.	bought	52,200	0.87	60,000	-
Jun 14, 2022	shv management services, llc	bought	52,200	0.87	60,000	-
Jun 13, 2022	shv management services, llc	bought	91,000	0.91	100,000	-

Which funds bought or sold MTEM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-0.48	-7,843	11,650	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-1,000	-	-%
May 15, 2024	CANTOR FITZGERALD, L. P.	new	-	41,845	41,845	0.01%
May 15, 2024	BVF INC/IL	reduced	-1.84	-798,728	1,169,810	0.03%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	13.00	13.00	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	reduced	-12.15	-515,880	576,130	-%
May 15, 2024	CAXTON CORP	unchanged	-	-203,930	306,580	1.75%
May 15, 2024	Bellevue Group AG	unchanged	-	-1,534,430	2,306,800	0.04%
May 15, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	unchanged	-	-528,366	794,322	0.22%
May 15, 2024	BARCLAYS PLC	unchanged	-	-	1,000	-%

Are Funds Buying or Selling MTEM?

Are funds buying MTEM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MTEM

No. of Funds

Unveiling Molecular Templates Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 29, 2024	longitude capital partners iii, llc	4.6%	309,819	SC 13D/A
Apr 02, 2024	sante health ventures i lp	6.2%	407,773	SC 13D/A
Feb 14, 2024	silverarc capital management, llc	6.60%	354,608	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	985%	596,145	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	5.4%	289,378	SC 13G/A
Feb 14, 2024	lytton laurence w	4.3%	232,951	SC 13G/A
Feb 13, 2024	bb biotech ag	19.2%	1	SC 13G/A
Oct 24, 2023	longitude capital partners iii, llc	5.7%	309,819	SC 13D/A
Jul 20, 2023	lytton laurence w	5.1%	4,142,361	SC 13G
Jul 18, 2023	adage capital partners gp, l.l.c.	5.45%	4,391,489	SC 13G

Recent SEC filings of Molecular Templates Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 03, 2024	EFFECT	EFFECT
May 03, 2024	424B3	Prospectus Filed
Apr 29, 2024	SC 13D/A	13D - Major Acquisition
Apr 25, 2024	10-K/A	Annual Report
Apr 25, 2024	S-3	S-3
Apr 12, 2024	8-K	Current Report
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading

Peers (Alternatives to Molecular Templates Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Molecular Templates Inc News

Latest updates

Molecular Templates Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	58.0%	11,086,000	7,016,000	6,796,000	6,865,000	36,629,000	2,611,000	4,240,000	4,417,000	8,486,000	17,964,000	2,379,000	15,134,000	3,220,000	3,497,000	4,298,000	6,909,000	4,141,000	6,197,000	3,618,000	5,447,000	7,008,000
Operating Expenses	-10.1%	11,136,000	12,387,000	11,933,000	18,608,000	24,844,000	23,670,000	27,907,000	27,931,000	29,117,000	27,265,000	31,908,000	30,049,000	29,549,000	29,414,000	27,169,000	36,826,000	26,278,000	22,601,000	41,881,000	14,848,000	13,389,000
S&GA Expenses	-100.0%	-	3,591,000	4,309,000	5,195,000	5,802,000	6,080,000	5,934,000	6,566,000	7,620,000	7,952,000	9,027,000	8,922,000	8,181,000	7,116,000	7,547,000	6,412,000	5,647,000	6,028,000	4,509,000	4,605,000	4,935,000
R&D Expenses	-15.8%	7,405,000	8,796,000	7,624,000	13,413,000	19,042,000	17,590,000	21,973,000	21,365,000	21,497,000	19,313,000	22,881,000	21,127,000	21,368,000	22,298,000	19,622,000	30,414,000	20,631,000	16,573,000	15,249,000	10,243,000	8,454,000
EBITDA Margin	-100.7%	0.00	0.01	-0.30	-0.69	-1.02	-4.14	-2.00	-2.30	-1.55	-1.92	-3.85	-3.32	-5.79	-5.31	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	1,182,000	1,111,000	1,024,000	915,000	803,000	753,000	767,000	756,000	408,000	317,000	320,000	363,000	85,000	163,000	170,000	170,000	170,000	174,000
Income Taxes	-	-	-	-	-	-	27,000	26,000	-	-	-	-	-	-	-	-	-	5,000	-	-	-	-
Earnings Before Taxes	100.0%	-	-3,959,000	-4,153,000	-10,868,000	10,845,000	-22,022,000	-24,612,000	-24,420,000	-21,611,000	-10,243,000	-30,387,000	-15,601,000	-26,778,000	-28,445,000	-23,225,000	-31,228,000	-22,013,000	-15,881,000	-38,219,000	-9,153,000	-6,168,000
EBT Margin	-80.4%	-0.26	-0.14	-0.50	-0.93	-1.26	-4.69	-2.30	-2.61	-1.77	-2.15	-4.18	-3.60	-6.12	-5.57	-	-	-	-	-	-	-
Net Income	114.5%	572,000	-3,948,000	-4,153,000	-10,868,000	10,845,000	-22,033,500	-24,638,000	-24,451,000	-21,611,000	-10,243,000	-30,387,000	-15,601,000	-26,778,000	-28,445,000	-23,225,000	-31,228,000	-22,018,000	-15,881,000	-38,219,000	-9,153,000	-6,168,000
Net Income Margin	-308.6%	-0.58	-0.14	-0.50	-0.93	-1.26	-4.69	-2.31	-2.61	-1.77	-2.15	-4.18	-3.60	-6.12	-5.57	-	-	-	-	-	-	-
Free Cashflow	0.8%	-5,244,000	-5,287,000	-7,534,000	-9,655,000	-19,544,000	-18,744,000	-25,413,000	-19,816,000	-28,249,000	-23,344,000	-26,133,000	-26,685,000	41,779,000	-24,386,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-23.4%	27.00	35.00	44.00	36.00	79.00	98.00	119	141	163	192	218	245	252	140	169	142	161	174	93.00	131	141
Current Assets	-36.3%	11.00	17.00	23.00	12.00	52.00	68.00	87.00	111	132	148	177	205	209	99.00	130	108	124	140	64.00	80.00	91.00
Cash Equivalents	-41.2%	7.00	12.00	16.00	5.00	39.00	32.00	22.00	27.00	20.00	25.00	28.00	43.00	99.00	25.00	33.00	28.00	34.00	85.00	15.00	17.00	38.00
Net PPE	-15.0%	6.00	7.00	9.00	10.00	13.00	15.00	16.00	18.00	19.00	19.00	20.00	21.00	22.00	22.00	21.00	20.00	19.00	18.00	14.00	9.00	7.00
Liabilities	-31.8%	21.00	31.00	37.00	44.00	80.00	113	114	115	116	127	146	147	143	81.00	85.00	87.00	77.00	71.00	40.00	42.00	44.00
Current Liabilities	-50.5%	9.00	17.00	22.00	27.00	30.00	57.00	50.00	46.00	45.00	47.00	47.00	45.00	77.00	38.00	40.00	41.00	44.00	36.00	24.00	26.00	28.00
Long Term Debt	-	-	-	-	-	36.00	36.00	36.00	36.00	36.00	35.00	35.00	35.00	15.00	15.00	15.00	15.00	3.00	3.00	3.00	3.00	3.00
LT Debt, Non Current	-	-	-	-	-	36.00	36.00	36.00	36.00	36.00	35.00	35.00	35.00	15.00	15.00	15.00	15.00	3.00	3.00	3.00	3.00	3.00
Shareholder's Equity	39.4%	6.00	4.00	7.00	-	-1.91	-15.13	4.00	26.00	47.00	66.00	72.00	97.00	108	59.00	84.00	56.00	84.00	103	53.00	89.00	96.00
Retained Earnings	0.1%	-452	-452	-448	-444	-433	-444	-422	-398	-373	-352	-341	-311	-295	-269	-240	-217	-186	-164	-148	-110	-100
Additional Paid-In Capital	0.2%	458	457	456	436	432	430	427	424	421	418	414	409	404	328	325	273	270	267	201	199	197
Shares Outstanding	0%	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	-	-	-	-	-	-	-
Float	-	-	-	-	18.00	-	-	-	29.00	-	-	-	266	-	-	-	410	-	-	-	168	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	0.8%	-5,244	-5,287	-7,534	-9,638	-19,361	-18,432	-24,427	-18,469	-27,696	-22,461	-24,810	-25,330	42,214	-21,506	-19,818	-24,324	-18,149	14,028	-16,394	-11,902	-10,976
Share Based Compensation	-20.1%	1,086	1,360	1,248	1,784	2,310	2,604	2,641	2,982	3,682	3,809	4,243	4,513	4,066	3,290	3,285	3,050	2,192	1,529	1,527	1,443	1,360
Cashflow From Investing	100.0%	-	-1.00	9.00	3,134	25,953	28,345	19,580	26,107	21,285	19,813	8,457	-50,323	-40,387	13,206	-22,592	7,674	-32,951	-8,220	14,383	-9,967	-35,920
Cashflow From Financing	-	-	-	18,384	-	-	-	9.00	-274	-	38.00	856	19,957	71,741	108	48,618	10,076	93.00	64,375	484	809	30.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MTEM Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 11,086	$ 36,629
Operating expenses:
Research and development	7,405	19,042
General and administrative	3,731	5,802
Total operating expenses	11,136	24,844
Income/(loss) from operations	(50)	11,785
Interest and other income, net	109	455
Interest and other expense, net	(31)	(1,395)
Change in valuation of contingent value right (Note 4)	544
Net income attributable to common stockholders	$ 572	$ 10,845
Net income per share attributable to common stockholders:
Basic (in dollars per share)	$ 0.11	$ 2.89
Diluted (in dollars per share)	$ 0.08	$ 2.89
Weighted average number of shares used in net income/(loss) per share calculations:
Basic (in shares)	5,374,268	3,756,711
Diluted (in shares)	7,015,864	3,756,711
Research and development revenue
Total revenue	$ 10,924	$ 33,627
Grant revenue
Total revenue	$ 162	$ 3,002

MTEM Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,779	$ 11,523
Prepaid expenses	1,200	2,195
Grants revenue receivable	412	250
Other current assets	2,299	2,804
Total current assets	10,690	16,772
Operating lease right-of-use assets	8,647	9,161
Property and equipment, net	6,284	7,393
Other assets	1,498	2,057
Total assets	27,119	35,383
Current liabilities:
Accounts payable	2,681	1,523
Accrued liabilities	2,748	4,279
Deferred revenue, current		9,031
Other current liabilities	3,152	2,488
Total current liabilities	8,581	17,321
Operating lease liabilities, long term portion	9,075	9,742
Contingent value right liability	2,158	2,702
Other liabilities	1,435	1,406
Total liabilities	21,249	31,171
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, $0.001 par value per share: Authorized: 2,000,000 shares as of March 31, 2024 and December 31, 2023; Issued and outstanding: 250 shares as of March 31, 2024 and December 31, 2023
Common stock, $0.001 par value per share: Authorized: 150,000,000 shares as of March 31, 2024 and December 31, 2023; Issued and outstanding: 5,374,268 shares as of March 31, 2024 and December 31, 2023	5	5
Additional paid-in capital	458,185	457,099
Accumulated deficit	(452,320)	(452,892)
Total stockholders' equity	5,870	4,212
Total liabilities and stockholders' equity	$ 27,119	$ 35,383

About Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

CEO	Dr. Eric E. Poma Ph.D.
WEBSITE	mtem.com
INDUSTRY	Biotechnology
EMPLOYEES	111

Molecular Templates Inc Frequently Asked Questions

What is the ticker symbol for Molecular Templates Inc? What does MTEM stand for in stocks?

MTEM is the stock ticker symbol of Molecular Templates Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Molecular Templates Inc (MTEM)?

As of Fri May 17 2024, market cap of Molecular Templates Inc is 9.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MTEM stock?

You can check MTEM's fair value in chart for subscribers.

What is the fair value of MTEM stock?

You can check MTEM's fair value in chart for subscribers. The fair value of Molecular Templates Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Molecular Templates Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MTEM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Molecular Templates Inc a good stock to buy?

The fair value guage provides a quick view whether MTEM is over valued or under valued. Whether Molecular Templates Inc is cheap or expensive depends on the assumptions which impact Molecular Templates Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTEM.

What is Molecular Templates Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MTEM's PE ratio (Price to Earnings) is -0.52 and Price to Sales (PS) ratio is 0.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MTEM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Molecular Templates Inc's stock?

In the past 10 years, Molecular Templates Inc has provided -0.281 (multiply by 100 for percentage) rate of return.